ACE — Ascelia Pharma AB Balance Sheet
0.000.00%
- SEK305.67m
- SEK255.81m
Annual balance sheet for Ascelia Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 185 | 262 | 150 | 21.9 | 75.3 |
Net Total Receivables | 2.6 | 5.56 | 4.53 | 2.46 | 5.69 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 196 | 275 | 161 | 28.9 | 83.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.99 | 1.82 | 0.625 | 1.06 | 0.124 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 255 | 333 | 219 | 87.1 | 141 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18.4 | 25.1 | 37.5 | 12.6 | 62 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 19.3 | 25.7 | 37.7 | 12.7 | 62 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 236 | 308 | 181 | 74.3 | 78.9 |
Total Liabilities & Shareholders' Equity | 255 | 333 | 219 | 87.1 | 141 |
Total Common Shares Outstanding |